Literature DB >> 9092569

Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-kappaB.

B L Bennett1, R Cruz, R G Lacson, A M Manning.   

Abstract

Interleukin-4 (IL-4), an immunoregulatory cytokine secreted from activated T-helper 2 lymphocytes, eosinophils, and mast cells, stimulates the expression of a number of immune system genes via activation of the transcription factor, STAT6. However, IL-4 can concomitantly suppress the expression of other immune-related gene products, including kappa light chain, FcgammaRI, IL-8, and E-selectin. We demonstrate that IL-4 activates STAT6 in human vascular endothelial cells and that two STAT6 binding sites are present in the promoter of the E-selectin gene. IL-4-induced STAT6 binding does not activate E-selectin transcription but instead suppresses tumor necrosis factor alpha-induced expression of the E-selectin gene. STAT6 was found to compete for binding to a region in the E-selectin gene promoter containing overlapping STAT6 and NF-kappaB binding sites, effectively acting as an antagonist of NF-kappaB binding and transcriptional activation. This novel mechanism for IL-4-mediated inhibition of inflammatory gene expression provides an example of a STAT factor acting as a transcriptional repressor rather than an activator.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9092569     DOI: 10.1074/jbc.272.15.10212

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.

Authors:  Y Abu-Amer
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  IL-4 and IL-13 induce chemotaxis of human foreskin fibroblasts, but not human fetal lung fibroblasts.

Authors:  Tadashi Kohyama; Xiangde Liu; Fu-Qiang Wen; Tetsu Kobayashi; Shinji Abe; Stephen I Rennard
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

3.  Cytokine-mediated control of lipopolysaccharide-induced activation of small intestinal epithelial cells.

Authors:  Michael Lotz; Till König; Sandrine Ménard; Dominique Gütle; Christian Bogdan; Mathias W Hornef
Journal:  Immunology       Date:  2007-05-18       Impact factor: 7.397

4.  STAT-6-mediated control of P-selectin by substance P and interleukin-4 in human dermal endothelial cells.

Authors:  Yasuhiro Miyazaki; Takahiro Satoh; Kiyoshi Nishioka; Hiroo Yokozeki
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 5.  Role of transcription factors in inflammatory lung diseases.

Authors:  I Rahman; W MacNee
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

6.  Role of NADPH oxidase in interleukin-4-induced monocyte chemoattractant protein-1 expression in vascular endothelium.

Authors:  Yong Woo Lee; Won Hee Lee; Paul H Kim
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

Review 7.  IL-4: an important cytokine in determining the fate of T cells.

Authors:  J L Silva-Filho; C Caruso-Neves; A A S Pinheiro
Journal:  Biophys Rev       Date:  2014-01-09

8.  NF-κB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-κB pathways.

Authors:  Minjun Yu; Xiulan Qi; Jose L Moreno; Donna L Farber; Achsah D Keegan
Journal:  J Immunol       Date:  2011-07-06       Impact factor: 5.422

9.  Inhibition of suppressive T cell factor 1 (TCF-1) isoforms in naive CD4+ T cells is mediated by IL-4/STAT6 signaling.

Authors:  Elisabeth Maier; Daniel Hebenstreit; Gernot Posselt; Peter Hammerl; Albert Duschl; Jutta Horejs-Hoeck
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

10.  Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability.

Authors:  Diana R Gutsaeva; Pedro Montero-Huerta; James B Parkerson; Shobha D Yerigenahally; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.